Malaria endemic countries need PQ as an essential tool for malaria elimination to fill the substantial gap left by tafenoquine’s restricted licence of use in G6PD normal and minimally G6PDd deficient vivax-infected patients [31] and for blocking the transmission of artemisinin-resistant P. falciparum [1], which is well established in SE Asia [32] and is now emerging independently as a new threat in large parts of eastern Africa [33–36]. This evidence concerns the gene G6PD and malaria.